Evidence map›Paper›PMID 41883185›Full record

ArticleChemical biology & drug design2026

High-Throughput Platform for Discovery of Chemical Inhibitors of Heat Shock Protein 70 (Hsp70): Adaptation for the Specialized Bacterial HscA-HscB-IscU Complex.

Arielle Shkedi, Aneta Grabinska-Rogala, Jason Hernandez, Rafał Dutkiewicz, Jaroslaw Marszalek, Jason E Gestwicki

Abstract read
In one paragraph

Article in Chemical biology & drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Arielle ShkediDepartment of Pharmaceutical Chemistry and the Institute for Neurodegenerative Diseases, University of California San Francisco, San Francisco, California, USA.
Aneta Grabinska-RogalaDepartment of Pharmaceutical Chemistry and the Institute for Neurodegenerative Diseases, University of California San Francisco, San Francisco, California, USA.
Jason HernandezDepartment of Pharmaceutical Chemistry and the Institute for Neurodegenerative Diseases, University of California San Francisco, San Francisco, California, USA.
Rafał DutkiewiczIntercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdansk, Poland.
Jaroslaw MarszalekIntercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdansk, Poland.
Jason E GestwickiDepartment of Pharmaceutical Chemistry and the Institute for Neurodegenerative Diseases, University of California San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-6125-3154

Funding

Molecular Chaperones and Small MoleculesR01NS059690 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jason E Gestwicki · 2008 to 2026
$7.9M
NIH HHS NS059690NINDS NIH HHS R01 NS059690
6 · The paper itself

Abstract

Adenosine triphosphatases (ATPases) power essential cellular processes, but they commonly achieve full activity only within multi-protein assemblies, where cofactors and partner proteins tune their function. Yet, most high-throughput screening (HTS) campaigns that target ATPases tend to use highly purified enzymes without these important partners. Here we present a high-throughput platform for discovering small-molecule modulators of the bacterial heat shock protein (Hsp70) system: HscA-HscB-IscU, a promising anti-bacterial target. In this multi-protein complex, HscA has ATPase activity that is stimulated by HscB and IscU, such that inhibitors might act at either the enzyme active site or at protein-protein interactions (PPIs). To enable discovery of such molecules, we reconstituted purified HscA, HscB, and IscU, optimized their ratios to favor the active complex and then miniaturized a quinaldine red-based, phosphate detection assay to 384-well plates (Z' = 0.68). A pilot screen of ~2000 bioactive compounds identified 253 primary hits, suggesting an abnormally high hit rate (13.6%); however, many of these signals were attributable to compound insolubility and could be triaged using aggregation-detection strategies. Collectively, this workflow establishes a scalable platform for discovering chemical probes of the HscA-HscB-IscU system. More broadly, this work provides the foundation for HTS campaigns targeting reconstituted, multi-protein complexes containing ATPase activity.

Indexed as

Bacterial ProteinsEscherichia coli ProteinsHigh-Throughput Screening AssaysHSP70 Heat-Shock ProteinsSmall Molecule LibrariesAdenosine TriphosphatasesDrug DiscoveryEscherichia coliProtein BindingAdenosine TriphosphatasesBacterial ProteinsEscherichia coli ProteinsHSP70 Heat-Shock ProteinsSmall Molecule Libraries

Identifiers

PMID41883185
PMCPMC13250878

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.